Users most often reported increased appetite, unlike the stomach issues seen in trials. The researchers say it can't show retatrutide caused any of it.
Recap by typeshit. Full story at EurekAlert!.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
A surgeon on social media says the FDA has received two death reports involving black-market retatrutide. No official FDA statement is linked.
In a SURPASS-CVOT subgroup with heart failure, the combined outcome hit 18.2% on tirzepatide vs 21.5%, mostly from fewer deaths. Authors call it hypothesis generating.
Dr Deutsch discusses two reported fatalities he says may be related to retatrutide use. The link has not been confirmed.
Loading…